2026-11-11 · 2026-11 / week-2
Gevo’s record quarter includes a $20M banked-credit true-up; the long has no 5% downside bound
Gevo’s record quarter includes a $20M banked-credit true-up; the long has no 5% downside bound
- Published: 11 November 2026, 16:01 Singapore time.
- Research cutoff: 11 November 2026, 3:01 a.m. U.S. Eastern time, pre-market.
- Classification: U.S.-listed long screen, Reject / no trade. This is research, not personalized advice.
Summary: Gevo reported Q3 revenue of $83.0 million, net income of $23 million and adjusted EBITDA of $44 million. But $29.4 million of Q3 revenue came from Canadian Clean Fuel Regulation credits, including a $20 million true-up for credits accumulated before regulatory approval; nine-month operating cash flow was only $12.0 million after $41.1 million of tax-credit sale proceeds and $51.6 million of property investment. The last completed regular close was $1.39. The pre-result analyst panel’s $2.50 median target implies +79.9%, while its $1.20 low-target stress implies -13.7%; neither is a valuation or downside floor. The scenario map cannot support a credible adverse bound within 5%. Reject; no trade. [1][2][3][4]
Opportunity Ranking
The U.S.-long screen compared three fresh Q3 mechanisms: Gevo’s credit-supported earnings and carbon monetization; CoreWeave’s AI infrastructure backlog against capex and interest; and Amprius’s fast revenue growth against negative adjusted EBITDA and the cash-to-capacity bridge. SPY was the broad-market control. The selected screen is first for information value, not because it is the best executable long. [1][5][8][11]
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Gevo (GEVO) | Long screen | The $44M Q3 adjusted EBITDA headline includes a $20M true-up from previously accumulated Canadian credits; ongoing cash conversion and 45Z value remain to be demonstrated. | Q3 10-Q and release filed Nov. 10; analyst targets last updated Oct. 9. | Q4 credit receipts; North Dakota debottleneck expected by year-end; next report date unverified. | Current ownership, short interest and options positioning not verified. | Reject: median-target base +79.9%, low-target stress -13.7%; no evidence-based 5% adverse bound. | Nasdaq common; spread, depth, venue quality, volume quality and exit capacity unverified. | Credit timing, 45Z realization, debt-funded capacity and small-cap price gaps. [1][2][3][4] |
| 2 | CoreWeave (CRWV) | Long screen | Q3 revenue rose to $3.66B and revenue backlog reached $132.5B, but FY26 capex guidance is $37B-$39B and Q4 interest expense is guided at $1.05B-$1.15B. | Q3 SEC exhibit and price/forecast pages checked Nov. 11. | Customer prepayments, delivery milestones and power deployment; exact cash receipts remain conditional. | 42-analyst target panel; current flows and positioning not verified. | Reject: analyst low $39 is -20.0% from the $48.73 close; backlog is not unconditional revenue. | Nasdaq common; high headline volume, but executable spread/depth and exit capacity not audited. | Debt, customer concentration, power, delivery timing and financing needs. [5][6][7] |
| 3 | Amprius (AMPX) | Long screen | Q3 revenue rose 83% y/y and FY26 revenue guidance reached $145M, while adjusted EBITDA remained negative $1.0M. | Q3 SEC exhibit and November 10 quote checked. | Revenue conversion, gross margin and production scale; next report date unverified. | Current ownership and positioning not verified. | Reject: $14 analyst-low target is +52.7% from $9.17, but analyst targets do not bound a loss or establish fair value. | NYSE common; spread, depth, venue quality and exit capacity unverified. | Growth may require more capital before unit economics are durable. [8][9][10] |
| 4 | SPY | Broad-market control | Nov. 10 close $749.92, down 0.37%; no issuer-specific catalyst. | Nov. 10 regular-session row. | Broad earnings and macro events. | Not used as an issuer-positioning thesis. | Control only: no standalone 10/5 setup tested. | Broad ETF; execution review not performed. | Index returns do not resolve Gevo’s credit and cash-conversion path. [11] |
Why this one now: The new 10-Q separates current production from a $20 million CFR-credit true-up and shows that nine-month operating cash flow included substantial tax-credit sale proceeds. The market then displayed a separate after-hours price jump. Neither the headline profit nor that mark proves recurring cash flow or regular-session acceptance.
What should surprise the reader: Gevo’s own release expects more than $70 million of adjusted EBITDA in 2027, but also identifies roughly $20 million of 2026 non-recurring CFR revenue and an additional 45Z contribution that remains subject to third-party validation. The bull case is credible; the timing and cash conversion are not yet settled. [1]
Why This Is the Most Useful No-Trade Screen Now
The positive case is real. Gevo’s North Dakota ethanol segment produced 19 million gallons in Q3 versus 17 million a year earlier; the company says most of the increase reflected maintenance completed before Q3 this year but during Q3 last year. It reported $44 million adjusted EBITDA, $41 million of quarterly operating cash flow and $68 million of quarter-end cash. It expects over $50 million of 2026 carbon-business revenue, says it contracted $70 million of 2026 Section 45Z tax-credit sales in October, and expects more than $70 million of 2027 adjusted EBITDA. Its 10-Q says the 45Z credit period was extended through 2029. These are issuer-reported results and expectations, not independent proof of a durable equity value. [1][2]
The countercase is in the bridge. Q3 included $29.4 million of Canadian CFR-credit revenue, of which $20.0 million was a true-up for credits accumulated before regulatory approval. Nine-month operating cash flow was $12.0 million, including $41.1 million of cash proceeds from production-tax-credit sales; nine-month property investment was $51.6 million. Cash fell $49.4 million during the nine months to $67.6 million. Total debt was $175.0 million gross and $167.8 million net of issuance costs at September 30. The 10-Q also reports a $172.5 million nine-month GAAP loss, including a $135.8 million asset impairment and a $40.3 million allowance for credit losses on refundable deposits. Those are not equivalent to recurring cash burn, but they make asset and project quality part of the underwriting. These facts do not prove distress; they do show why the Q3 profit headline is not a clean run-rate measure. [2]
Management says the current 45Z model may add more than $10 million of annual gross profit from existing RNG assets, subject to third-party validation. The 2027 EBITDA outlook stays above $70 million, a strong counterpoint to a simple “one-time quarter” thesis. Yet 2026 adjusted EBITDA guidance above $90 million is expressly supported in part by the non-recurring CFR true-up. The next test is whether operating cash remains positive after tax-credit proceeds, working capital and required plant investment. [1][2]
Why This Can Move More Than 5% Soon
StockAnalysis reports a Nov. 10 regular close of $1.39, down 5.44%. Gevo’s release was timestamped 4:01 p.m. ET, one minute after that close; the page later showed $1.60 after hours at 7:59 p.m., up 15.11%. The after-hours mark is reference context only. No post-result regular session had occurred by the 3:01 a.m. ET research cutoff, and price movement alone says nothing about spread, depth or realistic exit capacity. [3][12]
The next observable catalysts are the cash realization of the contracted 2026 45Z credits, reported results from the North Dakota debottleneck, and the next filed cash-flow statement. The company expected the debottleneck project to be complete by year-end 2026. The company described its planned expansion as progressing toward financing, not as funded or completed. [1]
10/5 Asymmetry Gate
The reference-only map uses the latest completed regular close, $1.39 at 4:00 p.m. ET on November 10. StockAnalysis’s forecast page separately displayed $1.405 at close and $1.59 after hours at 7:55 p.m.; its history page shows $1.39 and $1.60 at 7:59 p.m. These are distinct page/time observations, not an executable quote; the map uses the historical close and does not average them. The analyst page’s targets were last updated October 9, before this Q3 release. [3][4]
- Reference base: $2.50, the analyst panel’s median target; $2.50 / $1.39 - 1 = +79.9%.
- Adverse stress: $1.20, the panel’s low target; $1.20 / $1.39 - 1 = -13.7%. This is a stale analyst stress, not a floor.
- Gross base-to-low-target stress ratio: ($2.50 - $1.39) / ($1.39 - $1.20) = 5.84:1.
- Five-percent boundary: $1.3205; the $1.20 low-target stress is $0.1205 below it.
The median is materially below the reported $5.05 mean because the high target is $14. The target panel is old and does not model credit receipts, dilution, capex or the financing of planned expansion. It cannot establish that a credible adverse path is limited to 5%.
Price Target and Probability Map
These are subjective scenario weights applied to secondary analyst anchors, not observed frequencies or a fundamental valuation. The top case gets 5% because only one listed estimate is $14 and the filings do not support that value with a reconciled model. The median target receives 60% as the central published anchor. The low-target stress receives 35% because the one-time credit contribution, cash conversion and future project financing remain uncertain.
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 5% | $14.00 | +907.2% | 12 months | Carbon and fuel economics compound; the single $14 analyst target is reached. | Low; analyst outlier, stale |
| Base Case | 60% | $2.50 | +79.9% | 12 months | Carbon-credit monetization continues and Gevo approaches the median analyst target. | Low; pre-result target, not fair value |
| Bottom Case | 35% | $1.20 | -13.7% | 12 months | The CFR true-up does not recur, 45Z value or realized credit prices disappoint, and the low analyst target is reached. | Low; stress, not a floor |
| Invalidation | n/a | Rebuild after the next filed cash bridge | n/a | Next reporting cycle | Recurring operating cash remains positive after capex and credit-sale proceeds, while 45Z revenue and 2027 EBITDA are independently reconciled. | Medium, conditional on filing |
- Probability-weighted expected price: $2.62, or +88.5% gross from $1.39 before costs. This is a target-weighted sensitivity, not fair value.
- Outlier sensitivity: removing the 5% $14 case and renormalizing base/bottom weights gives about $2.02, or +45.4% gross. The result still depends on stale analyst targets.
- Current market level and timestamp: $1.39 regular close, Nov. 10, 4:00 p.m. ET; separate $1.60 after-hours mark at 7:59 p.m. ET.
- Primary instrument: Nasdaq common stock, unlevered, if the screen is rebuilt.
- 10/5 favorable base move: +79.9% from the regular close, reference-only.
- 10/5 adverse bound: not established within -5%; the stale low-target stress is -13.7% and is not a floor.
- 10/5 measurement basis: Reference-only; no executable entry.
- 10/5 status: Reject. The reference low-target stress exceeds 5%; live execution and a current post-result cash/credit bridge are unavailable.
- Confidence: Low. The target panel predates the result and no source supplies a reconciled common-equity valuation.
What Should Surprise the Reader
The analyst target page reports four analysts, a $5.05 mean, $2.50 median, $1.20 low and $14 high, but says the targets were last updated October 9. The four latest individual target actions shown on that same page are $14, $3.00, $1.70 and $2.00; their displayed arithmetic mean is $5.18, not $5.05. The page does not explain this difference. The mean and high are not a reliable post-result consensus signal; the median is used only as a reference anchor. [4]
The second surprise is the cash timing. The 10-Q records $12.0 million of nine-month operating cash flow and $41.1 million of proceeds from production-tax-credit sales within that figure. It also records $49.4 million of 45Z credits recognized as a noncash reduction to production costs. These are distinct accounting and cash states. Calling the whole $44 million Q3 adjusted EBITDA a recurring cash run rate would skip both. [2]
The Setup
- Scope: U.S.-listed equities, long only. GEVO is Nasdaq-listed common stock.
- Fresh primary evidence: Gevo’s Q3 release and Form 10-Q dated November 10; CoreWeave’s Q3 release and Amprius’s Q3 exhibit dated November 10.
- Archive boundary: No prior standalone GEVO article or signal was found. The main archive now includes a Nov. 11 09:18 SGT CoreWeave Q3 short screen plus earlier May and September capital-stack screens; CRWV is only a long-side comparator here. Amprius has a June warrant screen; the new Q3 results appear here only as a comparator, not a repeated thesis.
- Mechanism searches: “CFR credit true-up 45Z cash flow Gevo Q3”; “AI cloud backlog prepayments capex interest CoreWeave”; “silicon-anode battery revenue guide adjusted EBITDA cash Amprius.”
The Market Price
StockAnalysis/S&P Global lists GEVO at $1.39 at the Nov. 10 regular close, down $0.08 (-5.44%), with a $1.44 open, $1.39-$1.46 range and 7,244,639 shares. The company release was timestamped 4:01 p.m. ET, one minute after the regular close. The history page separately showed $1.60 after hours at 7:59 p.m. ET; the forecast page showed $1.405 at close and $1.59 after hours at 7:55 p.m. The observations are not averaged. The model uses the daily historical close, which predates the release. No later pre-market quote, spread, depth or exit capacity was verified. [3][4][12]
The 10-Q reports 247.376 million common shares as of November 6. Multiplying that dated denominator by $1.39 gives an approximate $344 million equity value; it is a four-day-old denominator and is not used as a precise market capitalization or valuation. At September 30, cash was $67.6 million against $167.8 million of debt carrying value net of issuance costs ($175.0 million gross); the simple cash-less-debt proxy is about $100.2 million before other claims, not a current valuation. [2]
The Mispricing
The possible disagreement is not simply “profitable quarter versus low price.” The bullish reading is that a carbon business, ethanol plant and tax-credit monetization can support more than $70 million of 2027 adjusted EBITDA, while Q3 operating cash flow was positive. The skeptical reading is that Q3 included $29.4 million of CFR-credit revenue, a $20 million true-up on credits accumulated before approval, and the nine-month cash picture remains thin after credit proceeds and plant capex.
The stock’s regular close fell 5.44% on Nov. 10, then the history page showed an after-hours rebound. That response does not identify the market’s expected recurring EBITDA or prove either a bargain or a failed thesis. I do not have sufficient reliable data to quantify a fundamental fair value accurately.
The Positioning
Current ownership changes, short interest, options exposure, borrow, spread, depth, venue quality and exit liquidity were not verified. The 7.24 million regular-session shares reported for Nov. 10 are volume, not proof of accumulation or forced flow. Positioning remains unknown. [3]
The Catalyst
- First post-result regular session: Q3 results were released at 4:01 p.m. ET on Nov. 10; the $1.60 after-hours mark followed at 7:59 p.m. The next regular session had not opened by the research cutoff. Test whether the after-hours repricing holds in regular trading; do not treat this as execution evidence. [3][12]
- 2026 45Z credit receipts: Gevo said in October that it had contracted sales of $70 million of expected 2026 45Z credits. Verify the transfer conditions, proceeds actually collected and how the cash appears in the filed statements. A contract announcement is not settled cash. [1]
- North Dakota debottleneck: the company expected completion by year-end 2026 and capacity of about 75 million gallons per year. Verify operating output, yields, cost and cash conversion, not just completion. [1]
- 2027 adjusted EBITDA: Gevo guided to more than $70 million. Reconcile the next filing’s carbon-credit revenue, production tax credits, ethanol volumes, RNG output, capex and debt service. Exact next report date is unverified. [1][2]
- Expansion financing: management said it was progressing toward financing for an expansion intended to roughly double ethanol and carbon-capture output from 2028. No financing close or completed project was verified. [1]
Cheapest disconfirmation: the next 10-Q’s cash-flow and credit-sale schedules. If operating cash is positive only when production credits are sold and capex stays below requirements, the claimed durable cash engine is not yet established.
The Payoff
The public analyst range suggests upside, but its latest updates predate the Q3 release and its mean is not reconciled to its listed individual actions. The $1.20 low target is a stress anchor, not a fair-value estimate or floor. No independent model links Gevo’s carbon-credit revenue, project capex, debt and share count to a current per-share value. A favorable target-weighted price does not resolve the downside bound or execution gaps.
The Kill Shot
The strongest counterargument is the company’s own 2027 outlook: more than $70 million of adjusted EBITDA after a $20 million non-recurring CFR true-up in 2026, plus an estimated greater than $10 million annual 45Z contribution from existing RNG assets. The SEC filing says the credit regime was extended through 2029. If those credit economics are validated and the new production capacity runs as planned, the present price could understate the business. [1][2]
The fragile assumption in the bear case is that the Q3 credit concentration is a reliable warning about normalized earnings. It may be temporary: Q3 also had higher fuel volumes, environmental-attribute sales and Q4 has contracted 45Z monetization. The market may be right to reward a new cash-generating carbon platform. But management’s estimates remain subject to validation, and the filing has not yet shown a durable post-capex cash record.
What Could Go Wrong
- Credit policy or value: 45Z recognition, carbon-credit prices, transfer timing or third-party validation may differ from management estimates.
- Quarterly timing: the $20 million CFR true-up related to previously accumulated credits; it will not recur on the same basis. [1][2]
- Cash conversion: nine-month CFO included $41.1 million of production-tax-credit sale proceeds, while property investment was $51.6 million; cash fell $49.4 million. [2]
- Debt and expansion: debt carrying value was $167.8 million net of issuance costs ($175.0 million gross); after $67.6 million cash, the simple net-debt proxy is about $100.2 million. Planned expansion financing is not verified as funded. [2]
- Denominator and dilution: shares outstanding rose from 242.46 million at Dec. 31, 2025 to 247.38 million at Sept. 30, 2026; current fully diluted claims were not audited in this run. [2]
- Price path: the $1.60 after-hours mark can reverse or gap; no executable bid/ask, depth, volume quality or realistic exit was verified. [3]
- Scenario risk: the $1.20 analyst low is not a floor; losses can exceed the mapped stress.
What Would Prove This Wrong
Rebuild the long only after a filed quarter shows credit-sale proceeds and 45Z receipts separately, positive operating cash after maintenance and growth capex, output from the completed debottleneck, and a fully funded expansion plan without material dilution. Reconcile the post-quarter share count and current debt. Then refresh the valuation from a new regular-session close and test a credible downside no worse than 5% after costs. Do not arm this record automatically.
Risk Audit
| Risk | Treatment |
|---|---|
| Q3 credit timing | $29.4M of CFR credits included a $20.0M true-up for previously accumulated credits. |
| Fuel volume comparison | Q3 output rose from 17M to 19M gallons, but the company attributed most of the change to prior-year maintenance timing. |
| Cash conversion | Nine-month CFO was $12.0M, including $41.1M production-tax-credit sale proceeds; property investment was $51.6M. |
| Prior project losses | Nine-month GAAP loss was $172.5M, including $135.8M asset impairment and a $40.3M allowance on refundable deposits; these are not recurring cash-flow measures. |
| Tax-credit estimates | Gevo’s >$10M annual 45Z benefit is an issuer estimate subject to third-party validation. |
| 2027 outlook | >$70M adjusted EBITDA is company guidance, not achieved results. |
| Debt | $175.0M gross debt; $167.8M carrying value after issuance costs; less $67.6M cash gives a simple $100.2M net-debt proxy. The debt table lists no 2026-2029 maturities. |
| Share count | 247.376M common shares as of Nov. 6; future financing or stock compensation can change the denominator. |
| Analyst targets | $1.20/$2.50/$14 are stale secondary anchors; $14 is an outlier, and none is a floor. |
| Positioning/execution | Current holdings, short interest, spread, depth, venue, volume quality and exit capacity are unverified. |
| Tail risks | Carbon-credit repricing, plant shutdown, refinancing, dilution, policy changes, gaps and halts can exceed the target stress. |
Best Trade Strategy
No trade. Do not buy from the $1.39 close, the $1.60 after-hours mark, the $2.50 median target or the Q3 earnings headline. Avoid options, leverage, margin, market orders and price-floor language. Reopen only after regular-session price acceptance, verified cash collection and a fresh model with a credible adverse move within -5%, base upside of at least 10%, a 2:1 reward-to-adverse ratio and positive value after costs. Keep entry null until every required execution gate passes.
Sources
- Gevo Q3 2026 results, SEC Exhibit 99.1, November 10 - Q3 revenue, CFR-credit true-up, EBITDA outlook, 45Z estimate, contracted 45Z sales and debottleneck status.
- Gevo Q3 2026 Form 10-Q - cash, debt, shares, cash flow, capex, 45Z and CFR accounting.
- GEVO Nov. 10 price history and after-hours mark - S&P Global-attributed regular-session row and separate 7:59 p.m. mark.
- GEVO analyst targets - four-analyst panel; target page last updated Oct. 9, before Q3 results.
- CoreWeave Q3 2026 results, SEC Exhibit 99.1 - revenue, backlog, guidance, capex and interest.
- CRWV Nov. 10 price history - regular close and separate after-hours mark.
- CRWV analyst targets - 42-analyst panel and target range.
- Amprius Q3 2026 results, SEC Exhibit 99.1 - Q3 revenue, margins, adjusted EBITDA and 2026 outlook.
- AMPX Nov. 10 price history - close and separate after-hours mark.
- AMPX analyst targets - 11-analyst panel and target range.
- SPY Nov. 10 price history - broad-market control.
- Gevo Q3 2026 results release timestamp, GlobeNewswire - company release stamped November 10, 2026, 4:01 p.m. ET.
Research Quality Scorecard
| Criterion | Score | Evidence and deduction |
|---|---|---|
| Market disagreement | 4/5 | Record Q3 earnings and a 15% after-hours rise meet a credit-rich cash bridge and stale, skewed targets. |
| Evidence base | 5/5 | Fresh SEC 10-Q and release establish the credit and cash bridge; price and target sources have dated limits. |
| Positioning and flows | 2/5 | Current holders, short interest, options and institutional flows are unverified. |
| Catalyst path | 3/5 | Credit receipts and the year-end debottleneck are observable; financing and next report date remain uncertain. |
| Payoff architecture | 2/5 | Median analyst target gives a large reference base, but downside is not bounded within 5% and no valuation model exists. |
| Invalidation discipline | 4/5 | Credit realization, capex, debt, output and dilution are monitorable in filed reports. |
| Differentiated insight | 4/5 | Separates a banked-credit true-up and tax-credit cash sales from recurring fuel economics. |
| Client value | 5/5 | The no-trade screen prevents record adjusted EBITDA from being mistaken for durable, post-capex cash. |
| Total | 29/40 | The score does not override the failed downside bound. Reject / no trade. |
Bottom Line
Gevo’s Q3 proves that its carbon and fuel operations can generate profits and cash in a strong quarter. It does not yet prove a repeatable post-capex cash engine: the quarter included $29.4 million of CFR credits, including a $20 million true-up, while nine-month operating cash flow was $12 million after credit-sale proceeds and capex was $51.6 million. The analyst median is a stale anchor, and the low-target stress already exceeds a 5% loss. Reject the long; no trade, null entry and execution disabled.
AI Illustration Prompt
Create a restrained financial editorial illustration of a low-carbon ethanol facility beside a carbon-credit ledger. Show a clean fuel tank, a line of labeled ethanol gallons, and a ledger with three separate entries: “CFR credits generated earlier,” “45Z contracted,” and “cash received.” Put a small $20M true-up stamp on a prior-period credit sheet, while a year-end debottleneck completion tag remains attached to the plant. Use warm paper, muted industrial green, graphite, off-white and a small amber accent. No logos, tickers, stock charts or trading instructions. Add a subtle readable “The Mispricing Desk” watermark at lower right.